# Creative Medical Technology Holdings, Inc.: Form 10-Q for the period ended Mar 31, 2020

- Company: [Creative Medical Technology Holdings, Inc.](/companies/celz.md) (CIK 1187953)
- Form: 10-Q
- Filed: 2020-05-15
- Accepted by EDGAR: May 15, 2020, 16:31 ET
- Period: 2020-03-31
- Accession: 0001104659-20-062662
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1187953/000110465920062662/tm2014547d1_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1187953/000110465920062662/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-01-01 to 2020-03-31 | $42.1k | us-gaap:Revenues |
| Cost of revenue | 3 months, 2020-01-01 to 2020-03-31 | $14.2k | us-gaap:CostOfRevenue |
| Gross profit | 3 months, 2020-01-01 to 2020-03-31 | $27.9k | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2020-01-01 to 2020-03-31 | $346.2k | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2020-01-01 to 2020-03-31 | −$335.0k | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2020-01-01 to 2020-03-31 | $323.2k | us-gaap:InterestExpense |
| Income tax | 3 months, 2020-01-01 to 2020-03-31 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-01-01 to 2020-03-31 | $3.7m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-01-01 to 2020-03-31 | $0.00 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2020-01-01 to 2020-03-31 | $0.09 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2020-01-01 to 2020-03-31 | 776,604,919 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2020-01-01 to 2020-03-31 | −$195.3k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Current assets | at 2020-03-31 | $49.5k | us-gaap:AssetsCurrent |
| Total assets | at 2020-03-31 | $469.3k | us-gaap:Assets |
| Current liabilities | at 2020-03-31 | $3.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-03-31 | $3.7m | us-gaap:Liabilities |
| Long-term debt | at 2020-03-31 | $1.5m | us-gaap:LongTermDebt |
| Shareholders' equity | at 2020-03-31 | −$3.2m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 13,746 characters.

*Management’s Discussion and Analysis of Financial Condition and Results of Operations analyzes the major elements of our balance sheets and statements of operations. This section should be read in conjunction with our Annual Report on Form 10-K for the year ended December 31, 2019, and our interim financial statements and accompanying notes to these financial statements included in this report. All amounts are in U.S. dollars.*

### Forward-Looking Statement Notice

This quarterly report on Form 10-Q contains forward-looking statements about our expectations, beliefs or intentions regarding, among other things, our product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from time to time, we or our representatives have made or may make forward-looking statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various filings made by us with the SEC, press releases or oral statements made by or with the approval of one of our authorized executive officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause our actual results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, those set forth in our most recent annual report referenced below.

This report identifies important factors which could cause our actual results to differ materially from those indicated by the forward-looking statements.

All forward-looking statements attributable to us or persons acting on our behalf speak only as of the date of this report and are expressly qualified in their entirety by the cautionary statements included in this report. We undertake no obligations to update or revise forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. In evaluating forward-looking statements, you should consider these risks and uncertainties.

### Overview

Creative Medical Technologies Holdings, Inc. is a commercial stage biotechnology company focused on urology, orthopedics and neurology using adult stem cell treatments.

We currently conduct substantially all of our commercial operations through Creative Medical Technologies, Inc. (“CMT”) our wholly-owned subsidiary. CMT markets and sells our CaverStem® and FemCelz® disposable kits utilized by physicians to perform autologous procedures that treat erectile dysfunction and female sexual dysfunction, respectively. Our CaverStem® and FemCelz® kits are currently available through physicians at 12 locations in the United States and Europe.

We are currently focused on expanding the commercial sale and use of CaverStem® and FemCelz® by physicians in the Unites States, Europe and South America, and commercializing our StemSpine® treatment for lower back pain. In the future, subject to the availability of capital, we will seek to further develop additional therapeutic products that utilize our proprietary intellectual property.

Our principal executive offices are located at 3008 W Lupine, Phoenix, AZ 85029.

During the first three months of 2020, we issued $168,300 in convertible notes with net proceeds of $145,000 to accredited investors.

During the three-month period ending March 31, 2020, we incurred interest expense of $49,714 arising from the third-party notes of $1,470,734.

#### Plan of Operations

We commenced marketing disposable stem cell concentration kits for the CaverStem® erectile dysfunction treatment in the fourth quarter of 2017 and the FemCelz® female sexual dysfunction treatment in March of 2019. The Company also announced the commercialization of the StemSpine procedure for lower back pain in the fourth quarter of 2019. We also continued to make progress towards filing an Innovative New Drug (IND) application for the Amniostem universal donor stem cell to treat stroke and neurodegenerative conditions. For the next 12 months our plan of operations is to continue to expand the market for the CaverStem® and FemCelz® procedures, launch the StemSpine procedure, file an IND application on Amniostem and partner with leading researchers to initiate the Amniostem trial. As of March 31, 2020, we had approximately $38,000 cash on hand. With an estimated monthly cash burn rate of approximately $100,000 based on historic trends and anticipated future revenues and expenses, management anticipates sufficient cash on hand and committed funds to meet operating expenses and costs of the current operations through at least May 2020. Historically, we have met our cash flow requirements through the sale of equity securities or borrowed funds. We intend to fund our business through sales of disposable stem cell concentration kits along with continuing to seek investments to meet our cash flow requirements, including both operating expenses and the balance of funding required to fund our sales efforts. The securities offered by us to potential investors have not been registered under the Securities Act of 1933, as amended (the “Act”), and may not be offered or sold in the U.S. absent registration or an applicable exemption from registration requirements. If we are unable to obtain further financing, we may seek alternative sources of funding or revise our business plan. We currently have no alternative sources for funding.

### Results of Operations – For the Three-Month Period Ended March 31, 2020 and 2019

***Gross Revenue.*** We generated $42,100 gross revenue for the three-month period ended March 31, 2020, in comparison with $50,800 for the comparable quarter a year ago. The decrease of $8,700 or 17% reflects the effects of the COVID-19 pandemic which caused the cessation of all elective procedures.

***Cost of Goods Sold***. We generated $14,196 cost of goods sold for the three-month period ended March 31, 2020, in comparison with $14,239 for the comparable quarter a year ago. The decrease of $43 or 0% is due to slightly lower gross margins as incentives were offered to new physician providers.

***Gross Profit/(Loss)***. We generated $27,904 in gross profit for the three-month period ended March 31, 2020, in comparison with $36,561 for the comparable quarter a year ago. The decrease of $8,657 or 24% is due to the lower revenues and reduced margins referenced above.

***General and Administrative Expenses.*** General and administrative expenses for the three-month period ended March 31, 2020, totaled $346,168, in comparison with $281,974, for the comparable quarter a year ago. The increase of $64,194, or 23% is primarily due to an increase of $30,000 in management fees and $41,282 in accounting and legal expenses.

***Research and Development Expenses.*** There were no research and development expenses for the three-month period ended March 31, 2020, and for the comparable quarter a year ago.

***Other Income / Expense.*** Other income for the three-month period ended March 31, 2020, totaled $4,077,516 in comparison with other expense of $546,667, for the comparable quarter a year ago. The increase of $4,624,183, or 846% is primarily due to a gain in the fair value of derivative liabilities of $4,400,739, a $131,319 reduction in interest expense and a loss during the three-month period ended March 31, 2019 of $357,292 associated with the extinguishment of convertible notes.

***Net Loss.*** For the reasons stated above, our net income for the three-month period ended March 31, 2020, totaled $3,742,480 in comparison to a loss of $797,366, for the comparable quarter a year ago.

### Liquidity and Capital Resources

Our principal source of liquidity has been funds received from the sale of our common stock and issuance of notes including convertible notes. Our experience to-date indicates the lenders are most likely to convert the debt into equity prior to or in lieu of full payment at maturity. Going forward, our short-term funding needs are expected to be satisfied by funds to be loaned to us by third parties and revenues generated from our Caverstem ED and FemCelz vaginal rejuvenation procedures. Our long-term liquidity needs are expected to be satisfied from future offerings of our equity securities. It is possible that CMH may provide future financing for us. We do not have any arrangements, agreements, or sources for long-term funding.

Our only commitments for expenditures relate to general and administrative costs, including reimbursements to our parent company for services performed by their executive officers on our behalf. During the next 12 months we also anticipate incurring expenses related to marketing activities for our ED and vaginal rejuvenation treatments.

For the next 12 months our plan of operations is to market our disposable kits and partner with leading researchers on investigator-initiated trials to advance our neurological programs. We believe that our current cash on hand would meet our cash flow requirements for only a few more months. If we are unable to obtain further financing, we may seek alternative sources of funding or revise our business plan. We currently have no alternative sources for funding.

Our financial statements included with this report have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have incurred substantial expenses and generated minimal revenues from operations during the periods covered by these financial statements. These factors raise substantial doubt about our ability to continue as a going concern. There is no assurance that we will be successful in meeting the continuing financial obligations of the company. Our financial statements do not include any adjustments that might result from the outcome of these uncertainties.

### Cash Flows

***Net Cash used in Operating Activities.*** We used cash in our operating activities due to our losses from operations. Net cash used in operating activities was $195,321 for the three-month period ended March 31, 2020 in comparison to $273,015 for the comparable period a year ago, a decrease of $77,694 or 28%. The decrease in cash used in operations was primarily related to increases in accounts payable and monies owed to CMH.

***Net Cash used in Investing Activities.*** There was no cash used in investing activities in the three-month periods ended March 31, 2020 and March 31, 2019, respectively.

***Net Cash From Financing Activities.*** In the three-month period ended March 31, 2020, we raised $145,000 through the issuance of convertible debt, retired no convertible debt and did not pay any prepayment premiums on retired convertible notes. In the three-month period ended March 31, 2019, we raised $575,890 through the issuance of convertible debt, expended $168,300 to retire convertible debt, and paid $19,154 in prepayment premiums on the retired convertible notes. The $243,436 or 63% decrease in cash flows from financing activities were primarily related to reduced levels of financing and no loan repayments.

### Basis of Presentation / Going Concern

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As of March 31, 2020, the Company had $38,327 of available cash and a working capital deficit of $3,602,038. For the three-month period ended March 31, 2020, the Company had $42,100 in revenue, $335,036 in operating loss and used net cash for operating activities of $195,321. These factors, among others, indicate that the Company may be unable to continue as a going concern for the next twelve months. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amount and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s ability to continue as a going concern is dependent upon its ability to obtain additional financing as may be required, and ultimately to attain sufficient cash flow from operations to meet its obligations on a timely basis. Management is in the process of negotiating various financing plans including access to ongoing credit facilities and possible sale of capital stock either in private or in public offerings and believes these steps may generate sufficient cash flow for the Company to continue as a going concern. If the Company is unsuccessful in these efforts, it may be required to substantially curtail or terminate its operations.

### Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future material effect on our consolidated financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity capital expenditures or capital resources.

## Controls and procedures

As filed, 1,602 characters.

### Evaluation of disclosure controls and procedures

As required by Rule 13a-15 under the Exchange Act, our management evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2020.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 15(d)-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (ii) is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

### Changes in internal control over financial reporting

There were no changes in our internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed May 15, 2020.
Source: SEC EDGAR, the filing index for accession 0001104659-20-062662. Last ingested by Listed: Nov 14, 2026, 19:08 ET. No prices; not investment advice.
